Affinage

NCR3LG1

Natural cytotoxicity triggering receptor 3 ligand 1 · UniProt Q68D85

Length
454 aa
Mass
50.8 kDa
Annotated
2026-06-10
59 papers in source corpus 25 papers cited in narrative 25 extracted findings
Cross-family judge faithfulness: 8/8 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

B7-H6 (NCR3LG1) is a B7-family cell-surface ligand that links cellular stress and malignant transformation to innate immune surveillance by directly engaging the activating NK receptor NKp30 to trigger NK cell cytotoxicity and cytokine secretion (PMID:19528259). The structural basis of this interaction is an antibody-like engagement in which NKp30 uses both faces of its Ig-like domain to contact CDR-like loops of the B7-H6 V-like domain, a geometry distinct from the inhibitory CTLA-4–B7 and PD-1–PD-L complexes (PMID:21422170). B7-H6 is largely absent from normal tissue and is induced on tumor cells and on proinflammatory CD14+CD16+ monocytes and neutrophils following TLR ligation or proinflammatory cytokines, including a G-CSF/NF-κB axis on tumor-infiltrating neutrophils (PMID:19528259, PMID:23687088, PMID:40054066). Its expression is transcriptionally driven by c-Myc and N-Myc binding the promoter and by an epigenetic program in which CBP/P300-dependent histone acetylation recruits BRD4 to promoter and enhancer elements (PMID:27622013, PMID:33796404), and it is further upregulated by chemotherapy, radiation, and heat shock to sensitize tumor cells to NK lysis (PMID:26472927). Surface B7-H6 is shed by the metalloproteases ADAM10 and ADAM17 to generate soluble ligand that, through chronic NKp30 engagement, downregulates NKp30 and impairs NK cell function—a route exploited as immune escape in cancer and HIV-2 infection (PMID:24780758, PMID:26137398, PMID:30325780, PMID:33671836). N-linked glycosylation governs function site-specifically: N43 glycosylation is required for NKp30-binding affinity, while N208 glycosylation stabilizes the protein at the membrane and prevents shedding (PMID:38035117). Beyond its role as an immune ligand, B7-H6 acts intracellularly to promote tumor cell proliferation, migration, and invasion through Ras/MEK/ERK, PI3K/Akt, and STAT3/AKT signaling, with c-Myc as a recurrent downstream effector (PMID:32606790, PMID:40240166, PMID:32322592). Viral antagonism is also documented: HCMV genes US18 and US20 target B7-H6 for endosomal degradation to evade NKp30-mediated recognition (PMID:28819195).

Mechanistic history

Synthesis pass · year-by-year structured walk · 12 steps
  1. 2009 High

    Established the existence and function of B7-H6, answering whether a dedicated tumor-restricted ligand drives NKp30 activation.

    Evidence Protein identification with binding and NK activation assays on human tumor cells

    PMID:19528259

    Open questions at the time
    • Did not resolve the structural basis of recognition
    • Regulation of its tumor-restricted expression unknown
  2. 2011 High

    Defined the structural basis of NKp30–B7-H6 recognition, showing an antibody-like engagement distinct from inhibitory B7-family complexes.

    Evidence X-ray crystallography of the NKp30–B7-H6 complex

    PMID:21422170

    Open questions at the time
    • Did not address post-translational requirements for binding
    • Affinity modulation in vivo not resolved
  3. 2013 High

    Identified how B7-H6 expression is induced, linking it both to inflammatory cell activation and to chromatin-level transcriptional control.

    Evidence TLR/cytokine stimulation of monocytes/neutrophils with vesicle fractionation; HDAC2/3 knockdown with promoter ChIP and reporter assays

    PMID:23687088 PMID:23801635

    Open questions at the time
    • Direct transcription factors not yet identified
    • Relationship between vesicle-associated and shed soluble forms unclear
  4. 2014 High

    Showed that surface B7-H6 is proteolytically shed, explaining the origin of soluble ligand and a mechanism limiting NK activation.

    Evidence ADAM10/ADAM17 pharmacologic inhibition and siRNA with flow cytometry, NK assays, and patient serum ELISA

    PMID:24780758

    Open questions at the time
    • Did not establish functional consequences of soluble form on NK receptors
    • Cleavage site not mapped
  5. 2015 Medium

    Demonstrated that chronic NKp30 engagement by soluble or surface B7-H6 downregulates NKp30 and other NK receptors, defining a self-limiting immune-escape circuit.

    Evidence Patient-derived NK cell phenotyping and functional assays across ovarian carcinoma, neuroblastoma, and HBV-related liver failure cohorts

    PMID:25877893 PMID:26137398 PMID:26241657

    Open questions at the time
    • Molecular mechanism of NKp30 downregulation not defined
    • Reversibility of receptor suppression untested
  6. 2015 Medium

    Established B7-H6 as the mediator of therapy-induced NK sensitivity, connecting cellular stress to immune recognition.

    Evidence Chemotherapy/radiation/heat-shock treatment with B7-H6 shRNA knockdown and NK cytotoxicity assays

    PMID:26472927

    Open questions at the time
    • Stress-responsive transcriptional sensors not identified
    • Single-lab finding
  7. 2016 High

    Identified c-Myc/N-Myc as direct transcriptional drivers of B7-H6 and showed that anti-B7-H6 antibodies can block activation sterically rather than competitively.

    Evidence Promoter ChIP, reporter assays, Myc knockdown/inhibition; crystallography of 17B1.3–B7-H6 with mutagenesis

    PMID:27622013 PMID:27663271

    Open questions at the time
    • Whether B7-H6 dimerizes physiologically remained unresolved
    • Myc cofactors at the promoter not mapped
  8. 2017 Medium

    Revealed viral antagonism of B7-H6, showing HCMV degrades the ligand to evade NK surveillance.

    Evidence HCMV infection with US18/US20 gene deletion, flow cytometry, endosomal degradation analysis

    PMID:28819195

    Open questions at the time
    • Molecular details of US18/US20-mediated targeting not fully resolved
    • Single lab
  9. 2019 Medium

    Extended the immune-escape paradigm to retroviral infection, showing HIV-2-infected T cells express B7-H6 to chronically suppress NKp30.

    Evidence Patient cohort flow cytometry and NK functional assays against B7-H6+ targets

    PMID:30325780

    Open questions at the time
    • Why HIV-2 induces rather than degrades B7-H6 not explained
    • Selective loss of cytolysis but not IFN-γ unexplained
  10. 2021 High

    Defined the epigenetic activation program and intracellular oncogenic signaling of B7-H6, beyond its ligand role.

    Evidence BRD4/CBP-P300 ChIP and inhibitor studies in AML; Ras/MEK/ERK phosphoproteomics and inhibitor rescue in lymphoma; atRA/c-Myc epistasis in leukemia

    PMID:32606790 PMID:33796404 PMID:34236140

    Open questions at the time
    • How a surface ligand drives intracellular kinase signaling mechanistically unclear
    • Receptor/effector linking B7-H6 to Ras/MEK/ERK not identified
  11. 2023 High

    Resolved site-specific roles of N-glycosylation, separating ligand-binding competence (N43) from membrane stability and shedding resistance (N208).

    Evidence Single-site mutagenesis, PNGase F/tunicamycin treatment, NK activation assays, phylogenetic analysis

    PMID:38035117

    Open questions at the time
    • Roles of the other four glycosylation sites undefined
    • Glycan structures themselves not characterized
  12. 2025 Medium

    Connected B7-H6 expression to RNA processing and downstream STAT3/AKT-driven proliferation, broadening its tumor-intrinsic functions.

    Evidence SNRPA RIP-seq and splice-junction PCR with gain/loss-of-function in HCC; G-CSF/NF-κB induction in neutrophils with apoptosis assays

    PMID:40054066 PMID:40240166

    Open questions at the time
    • Direct receptor mediating intracellular signaling unknown
    • Generalizability across tumor types untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a cell-surface ligand transduces the intracellular Ras/MEK/ERK, PI3K/Akt, and STAT3/AKT signals attributed to B7-H6 remains the central unresolved mechanistic question.
  • No defined intracellular signaling partner
  • Distinction between cell-autonomous and NKp30-engagement effects unresolved

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0048018 receptor ligand activity 2 GO:0060089 molecular transducer activity 1
Localization
GO:0005576 extracellular region 3 GO:0005886 plasma membrane 3
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-168256 Immune System 3 R-HSA-74160 Gene expression (Transcription) 2
Partners
ADAM10ADAM17NKP30

Evidence

Reading pass · 25 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2009 B7-H6 (NCR3LG1) is a tumor cell surface ligand that directly binds the activating NK cell receptor NKp30, triggering NKp30-mediated NK cell cytotoxicity and cytokine secretion. B7-H6 was not detected in normal human tissues but was expressed on human tumor cells. Protein identification, binding assays, NK cell activation assays The Journal of experimental medicine High 19528259
2011 Crystal structure of the NKp30–B7-H6 complex was determined. NKp30 uses both front and back β-sheets of its Ig-like domain to engage B7-H6 via the side and face of the β-sandwich; B7-H6 contacts NKp30 through CDR-like loops of its V-like domain in an antibody-like interaction distinct from CTLA-4–B7 and PD-1–PD-L inhibitory complexes. X-ray crystallography of NKp30–B7-H6 complex The Journal of experimental medicine High 21422170
2014 Tumor cell shedding of B7-H6 ectodomain is mediated by the cell surface metalloproteases ADAM10 and ADAM17. Pharmacologic inhibition or siRNA knockdown of ADAM10/ADAM17 increased membrane B7-H6 levels and enhanced NKp30-mediated NK cell activation; soluble B7-H6 was elevated in sera of melanoma patients. Pharmacologic inhibitors of ADAMs, siRNA-mediated gene attenuation, flow cytometry, NK cell activation assays, patient serum ELISA Cancer research High 24780758
2013 B7-H6 expression is induced on the surface of CD14+CD16+ proinflammatory monocytes and neutrophils upon TLR ligand stimulation or proinflammatory cytokines (IL-1β, TNF-α). A soluble form of B7-H6 is also produced by activated monocytes and neutrophils and is associated with membrane vesicles co-sedimenting with the exosomal fraction. In vitro stimulation assays, flow cytometry, fractionation/centrifugation of extracellular vesicles, in vivo patient cohort analysis Blood High 23687088
2013 B7-H6 mRNA and surface protein expression in tumor cells is downregulated by pan- or class I HDAC inhibitors (HDACi), and by siRNA-mediated knockdown of HDAC2 or HDAC3. This downregulation is associated with decreased B7-H6 reporter activity and reduced histone acetylation at the B7-H6 promoter, leading to impaired NKp30-dependent NK cell effector functions. Monoclonal antibody generation, siRNA knockdown of HDAC2/3, luciferase reporter assay, chromatin immunoprecipitation (ChIP), flow cytometry, NK functional assays Blood High 23801635
2015 Chronic engagement of NKp30 by soluble B7-H6 or tumor cell surface B7-H6 induces downregulation of NKp30 expression on NK cells, impairing NK cell IFN-γ production and cytolytic function against B7-H6-expressing target cells in ovarian carcinoma patients. Flow cytometry of tumor-associated NK cells from peritoneal fluids, in vitro functional assays with NK cells against B7-H6+ targets Oncoimmunology Medium 26137398
2015 Soluble B7-H6 in serum of high-risk neuroblastoma patients inhibits NK cell functions in vitro, and its serum concentration correlates with downregulation of NKp30 on circulating NK cells. NB cells expressing B7-H6 stimulate NK cells in an NKp30-dependent manner. In vitro NK cell functional assays with patient serum, flow cytometry, patient cohort analysis Science translational medicine Medium 25877893
2015 Standard tumor therapeutics including chemotherapy (cisplatin, 5-FU), radiation, non-lethal heat shock, and TNF-α upregulate B7-H6 expression on tumor cells, enhancing their susceptibility to NK cell lysis. B7-H6 shRNA knockdown dampened this sensitization, establishing B7-H6 as the mediator of therapy-induced NK sensitivity. Drug/radiation treatment of tumor cell lines, shRNA knockdown, NK cell cytotoxicity assays, flow cytometry The Journal of biological chemistry Medium 26472927
2016 The proto-oncogene c-Myc and N-Myc directly drive B7-H6 expression by binding a functional site in the B7-H6 promoter. Pharmacological inhibition or siRNA/shRNA-mediated knockdown of c-Myc or N-Myc significantly decreased B7-H6 expression in melanoma, pancreatic carcinoma, and neuroblastoma cell lines, and impaired NKp30-mediated NK cell degranulation. Luciferase reporter assays, chromatin immunoprecipitation (ChIP), siRNA/shRNA knockdown, pharmacologic Myc inhibition, NK cell degranulation assays Oncoimmunology High 27622013
2016 Crystal structure of anti-B7-H6 antibody 17B1.3 in complex with B7-H6 ectodomain (2.5 Å) revealed that 17B1.3 binds a site on B7-H6 completely distinct from the NKp30-binding site. Structure-based mutations designed to disrupt potential B7-H6 dimerization through this site did not diminish NKp30-mediated cell activation, indicating that the antibody inhibits NK cell activation by sterically interfering with cell-cell contact rather than blocking the NKp30–B7-H6 interaction. X-ray crystallography (2.5 Å), site-directed mutagenesis, NK cell activation assays Journal of molecular biology High 27663271
2017 Human cytomegalovirus (HCMV) upregulates B7-H6 expression upon infection, but the viral genes US18 and US20 counteract this by targeting B7-H6 for endosomal degradation, thereby reducing B7-H6 surface expression to evade NK cell recognition via NKp30. HCMV infection of cells, viral gene expression/deletion, flow cytometry, endosomal degradation pathway analysis Scientific reports Medium 28819195
2019 B7-H6 is expressed on the surface of HIV-2-infected CD4+ T cells, and chronic engagement of NKp30 by this surface B7-H6 induces downregulation of NKp30 on NK cells, impairing cytolytic function while maintaining IFN-γ overproduction, constituting a novel HIV-2 immune escape mechanism. Flow cytometry of NK cell phenotype and ligand expression in patient cohorts, functional NK cell assays against B7-H6+ target cells AIDS Medium 30325780
2020 B7-H6 promotes NHL cell proliferation, migration, and invasion via the Ras/MEK/ERK signaling pathway. B7-H6 knockdown reduced phosphorylation of Ras/MEK/ERK components, and the MEK inhibitor AZD8330 partially reversed proliferation and completely reversed migration/invasion induced by B7-H6 overexpression. siRNA/shRNA knockdown, quantitative phosphoproteomics, Western blot, B7-H6 overexpression, MEK inhibitor treatment, in vivo xenograft model, CCK-8 and Transwell assays OncoTargets and therapy Medium 32606790
2021 Soluble B7-H6 inhibits NK cell-mediated target cell killing and is associated with diminished cell surface expression of NKG2D and NCRs (NKp30, NKp40, NKp46). B7-H6 is only marginally released in association with extracellular vesicles (EVs), and EVs from B7-H6-expressing cells do not stimulate NK cell-mediated killing. Recombinant protein production in HEK293 cells, NK cell killing assays, flow cytometry, nano flow cytometry (NanoFCM) of EVs, ultracentrifugation fractionation International journal of molecular sciences Medium 33671836
2021 BRD4 acts as an epigenetic activator of B7-H6 transcription in AML cells. Histone acetylation mediated by CBP30/P300 facilitates BRD4 binding to the B7-H6 promoter, which recruits P-TEFb elongation factor to phosphorylate RNA polymerase II and activate B7-H6 transcription. BRD4 also co-binds with JMJD6 at a distal enhancer of the B7-H6 gene. Metformin modifies acetylation at the B7-H6 promoter, impairing BRD4 binding. BRD4 inhibition, ChIP, reporter assays, siRNA knockdown, metformin treatment, Western blot, flow cytometry, apoptosis assays Oncoimmunology High 33796404
2021 All-trans retinoic acid (atRA) induces leukemia cell resistance to NK cell cytotoxicity by downregulating B7-H6 expression via reduction of c-Myc, which in turn inhibits B7-H6 transcription. DNA methylation and HDAC inhibitors could not restore B7-H6 mRNA, indicating epigenetic modifications are not responsible; the effect was specifically dependent on c-Myc signaling. CRISPR/Cas9 B7-H6 knockout, siRNA c-Myc knockdown, real-time PCR, flow cytometry, Western blotting, NK cell cytotoxicity assays Cancer communications Medium 34236140
2023 B7-H6 contains 6 functional N-linked glycosylation sites. N43 and N208 glycosylation are conserved in jawed vertebrates and are essential for NK cell activation by B7-H6. Mechanistically, N208 glycosylation contributes to membrane stability and prevents B7-H6 shedding, while N43 glycosylation is required for B7-H6/NKp30 binding affinity. PNGase F digestion, tunicamycin blockade, single-site mutagenesis, SDS-PAGE, flow cytometry, NK cell activation assays, phylogenetic and structural analysis Frontiers in immunology High 38035117
2025 SNRPA promotes HCC cell proliferation and lenvatinib resistance via B7-H6 by facilitating B7-H6 pre-mRNA maturation: SNRPA binds B7-H6 pre-mRNA directly and contributes to its intron 2 splicing. B7-H6 in turn activates STAT3/AKT signaling, promoting G1-S cell cycle transition and inhibiting apoptosis. Nanopore full-length cDNA sequencing, RNA-binding protein immunoprecipitation (RIP-seq), exon-exon/exon-intron junction PCR, siRNA/overexpression gain/loss-of-function, Western blot, flow cytometry, in vivo xenograft model Bioscience trends Medium 40240166
2025 G-CSF derived from gastric cancer tumor microenvironment induces B7-H6 expression on tumor-infiltrating neutrophils via NF-κB signaling pathway activation. Blockade of B7-H6 on neutrophils promotes their apoptosis and shortens their lifespan. Flow cytometry, in vitro neutrophil stimulation with recombinant G-CSF and tumor supernatants, NF-κB pathway inhibition, apoptosis assays Neoplasia Medium 40054066
2024 CRISPR knockout of B7-H6 in CD4+ T cells reduced NK cell responses to HIV-1-infected cells in some donors, establishing that B7-H6 on HIV-infected cells contributes to NKp30-mediated NK recognition of HIV-infected cells. CRISPR editing of CD4+ T cells to knockout B7-H6, NK cell activation/response assays, ligand expression profiling by flow cytometry bioRxiv (preprint)preprint Medium bio_10.1101_2024.06.24.600449
2015 NKp30-B7-H6 interaction in HBV-related acute-on-chronic liver failure (ACLF) triggers NK cell upregulation of IL-32, which in turn induces apoptosis of hepatocytes (Huh7 cells) in a dose-dependent manner. In vitro NK-92 cells killed high-B7-H6-expressing Huh7 and B7-H6-transfected LO2 hepatocytes in an NKp30/B7-H6-dependent manner. Co-culture assays, CCK8 cytotoxicity assay, anti-NKp30 antibody stimulation, Annexin V/PI apoptosis assay, flow cytometry, immunochemistry in patient samples PloS one Medium 26241657
2020 B7-H6 is preferentially expressed in glioma stem-like cells (GSLCs) compared to parental glioma cell lines. Knockdown of B7-H6 by siRNA in GSLCs inhibited cell proliferation with decreased c-Myc expression and inactivation of PI3K/Akt and ERK/MAPK signaling pathways. RNMT (RNA guanine-7 methyltransferase) was identified as a downstream target co-expressed with B7-H6 and c-Myc; RNMT expression was inhibited upon B7-H6 knockdown. CRISPR-Cas9 knockout of B7-H6 in 293T cells also suppressed proliferation. siRNA knockdown, CRISPR-Cas9 knockout, Western blot, TCGA co-expression analysis, flow cytometry, proliferation assays Journal of immunology research Medium 32322592
2018 B7-H6 knockdown in glioma cell lines (HepG2 and SMMC-7721) decreased expression of C-myc, C-fos, and Cyclin-D1, and was accompanied by reduced cell proliferation, migration, invasion, and G1 cell cycle arrest, indicating B7-H6 regulates these oncogenic factors intracellularly. RNA interference (siRNA), CCK-8 proliferation assay, migration/invasion assays, Western blot, flow cytometry cell cycle analysis Cancer cell international Low 30186042
2018 Lipopolysaccharide (LPS) induces B7-H6 expression in glioma cell lines. B7-H6 knockdown increased E-cadherin and Bax expression while decreasing vimentin, N-cadherin, MMP-2, MMP-9, and survivin, suggesting B7-H6 promotes EMT and invasion-related signaling. LPS stimulation, siRNA knockdown, Western blot, cell viability/migration/invasion assays International immunopharmacology Low 29679856
2023 B7-H6 promotes migration and invasion of medulloblastoma (Daoy) cells by activating c-MYC, which in turn enhances F-actin cytoskeleton rearrangement and upregulates MMP-2 and MMP-9 expression. siRNA knockdown, plasmid overexpression, Transwell migration/invasion assays, Western blot, immunofluorescence staining of F-actin Medical oncology Low 36692844

Source papers

Stage 0 corpus · 59 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2009 The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. The Journal of experimental medicine 548 19528259
2014 Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer research 172 24780758
2015 B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape. Oncoimmunology 153 26137398
2015 Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Science translational medicine 124 25877893
2013 Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood 120 23687088
2013 Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 114 23801635
2011 Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6. The Journal of experimental medicine 100 21422170
2011 B7-H6/NKp30 interaction: a mechanism of alerting NK cells against tumors. Cellular and molecular life sciences : CMLS 90 21877119
2015 Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6. The Journal of biological chemistry 79 26472927
2015 B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer. International journal of clinical and experimental pathology 64 26464699
2016 The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells. Oncoimmunology 48 27622013
2012 Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity. Journal of immunology (Baltimore, Md. : 1950) 47 23066150
2016 Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma. International journal of oncology 41 26891663
2020 Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement. Journal of immunology (Baltimore, Md. : 1950) 40 33268483
2017 Human cytomegalovirus escapes immune recognition by NK cells through the downregulation of B7-H6 by the viral genes US18 and US20. Scientific reports 40 28819195
2017 High expression of B7-H6 in human glioma tissues promotes tumor progression. Oncotarget 39 28415577
2014 B7-H6 expression in non-small cell lung cancers. International journal of clinical and experimental pathology 39 25400778
2018 B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas. International immunopharmacology 36 29679856
2020 Anti-fouling SERS-based immunosensor for point-of-care detection of the B7-H6 tumor biomarker in cervical cancer patient serum. Analytica chimica acta 35 33161972
2017 The B7 Family Member B7-H6: a New Bane of Tumor. Pathology oncology research : POR 35 29086181
2018 Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition. American journal of cancer research 34 30094100
2020 Preferential Expression of B7-H6 in Glioma Stem-Like Cells Enhances Tumor Cell Proliferation via the c-Myc/RNMT Axis. Journal of immunology research 30 32322592
2021 Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 27 33839362
2017 Clinical significance of novel costimulatory molecule B7-H6 in human breast cancer. Oncology letters 24 28789456
2021 Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles. International journal of molecular sciences 23 33671836
2020 Immunological role and underlying mechanisms of B7-H6 in tumorigenesis. Clinica chimica acta; international journal of clinical chemistry 22 31904350
2022 The potential of B7-H6 as a therapeutic target in cancer immunotherapy. Life sciences 21 35697295
2018 B7-H6 expression in human hepatocellular carcinoma and its clinical significance [corrected]. Cancer cell international 19 30186042
2022 A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 18 36166004
2020 B7-H6 Promotes Cell Proliferation, Migration and Invasion of Non-Hodgkin Lymphoma via Ras/MEK/ERK Pathway Based on Quantitative Phosphoproteomics Data. OncoTargets and therapy 16 32606790
2020 B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines. BMC cancer 16 33172426
2020 Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer. BMC immunology 15 32138659
2015 NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure. PloS one 15 26241657
2020 Expression of a novel immune checkpoint B7-H6 ligand in human small cell lung cancer. Annals of translational medicine 14 32566616
2020 B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells. Investigational new drugs 14 32770284
2019 B7-H6-mediated downregulation of NKp30 in natural killer cells contributes to HIV-2 immune escape. AIDS (London, England) 14 30325780
2016 Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30. Journal of molecular biology 14 27663271
2021 Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer. Scientific reports 12 33824367
2021 B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma. Annals of translational medicine 11 33708955
2021 Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia. Oncoimmunology 11 33796404
2024 Harnessing B7-H6 for Anticancer Immunotherapy: Expression, Pathways, and Therapeutic Strategies. International journal of molecular sciences 8 39408655
2021 All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling. Cancer communications (London, England) 8 34236140
2021 Sevoflurane impedes glioma progression via regulating circ_0000215/miR-1200/NCR3LG1 axis. Metabolic brain disease 8 34460046
2015 Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody. Acta crystallographica. Section F, Structural biology communications 8 26057798
2023 Deficiency of N-linked glycosylation impairs immune function of B7-H6. Frontiers in immunology 7 38035117
2019 Expression of B7-H6 in chronic myeloid leukemia and its clinical significance. International journal of clinical and experimental pathology 7 31933861
2021 B7-H6 as a Diagnostic Biomarker for Cervical Squamous Cell Carcinoma. Genetic testing and molecular biomarkers 5 34280008
2018 Correction to: Expression of B7-H6 expression in human hepatocellular carcinoma and its clinical significance. Cancer cell international 4 30214376
2024 Enhancing NK cell-mediated tumor killing of B7-H6+ cells with bispecific antibodies targeting allosteric sites of NKp30. Molecular therapy. Oncology 3 39811682
2025 SNRPA promotes hepatocellular carcinoma proliferation and lenvatinib resistance via B7-H6-STAT3/AKT axis by facilitating B7-H6 pre-mRNA maturation. Bioscience trends 2 40240166
2025 Dual T/NK cell engagement via B7-H6-targeted bispecific antibodies and IL-15 eradicates chemo-resistant solid tumors. Frontiers in immunology 2 40873574
2023 B7-H6 enhances F-actin rearrangement by targeting c-MYC activation to promote medulloblastoma migration and invasion. Medical oncology (Northwood, London, England) 2 36692844
2025 Expression, regulation, function and clinical significance of B7-H6 on neutrophils in human gastric cancer. Neoplasia (New York, N.Y.) 1 40054066
2023 Affinity Maturation of the Natural Ligand (B7-H6) for Natural Cytotoxicity Receptor NKp30 by Yeast Surface Display. Methods in molecular biology (Clifton, N.J.) 1 37405651
2020 The B7 family molecules in oral squamous cell carcinoma: a systematic review. Part II: B7-1, B7-2, B7-H2, B7-H3, B7-H4, B7-H5 (VISTA), B7-H6 and B7-H7. Postepy dermatologii i alergologii 1 41001137
2016 [Elevated expression of B7-H6 in U87 cells-derived glioma stem like cells is associated with biological characteristics]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 1 27609569
2014 Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction. Journal of biological regulators and homeostatic agents 1 25001651
2025 Association between elevated serum soluble B7-H6 and infection in hemodialysis patients. Clinical and experimental nephrology 0 40425991
2022 Erratum: Long non-coding RNA LINC00673 promotes breast cancer proliferation and metastasis through regulating B7-H6 and epithelial-mesenchymal transition. American journal of cancer research 0 35261813

Missed literature

Know a paper Affinage missed for NCR3LG1? Flag it for the maintainers and the community.

No submissions yet.